PHVS: Oral deucrictibant matches injectable efficacy in HAE, with broad label and strong commercial prospects
Deucrictibant demonstrated high efficacy in phase III HAE trials, matching injectable therapies and offering oral convenience. Safety profile aligns with existing treatments, and regulatory filing is planned for next year. The product's broad mechanism and dual on-demand/prophylactic use position i…
Story updates
09:40:58 PM UTC
SquawkNews
Deucrictibant demonstrated high efficacy in phase III HAE prophylaxis, matching injectables and offering oral convenience. Safety profile aligns with existing therapies, and broad patient coverage—including normal C1—positions it for strong commercial uptake. Regulatory filings are planned for next…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.